際際滷shows by User: rpIBC / http://www.slideshare.net/images/logo.gif 際際滷shows by User: rpIBC / Thu, 12 May 2016 15:27:39 GMT 際際滷Share feed for 際際滷shows by User: rpIBC The time for SIEM /slideshow/the-time-for-siem/61953590 powersourcemagazinemay20162copy-160512152739
By Marc Maliza, Co-founder and CTO of RKON Technologies www.rkon.com ]]>
By Marc Maliza, Co-founder and CTO of RKON Technologies www.rkon.com ]]> Thu, 12 May 2016 15:27:39 GMT /slideshow/the-time-for-siem/61953590 rpIBC@slideshare.net(rpIBC) The time for SIEM rpIBC By Marc Maliza, Co-founder and CTO of RKON Technologies www.rkon.com <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/powersourcemagazinemay20162copy-160512152739-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> By Marc Maliza, Co-founder and CTO of RKON Technologies www.rkon.com
The time for SIEM from Rita Barry
]]> 178 5 https://cdn.slidesharecdn.com/ss_thumbnails/powersourcemagazinemay20162copy-160512152739-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Factors to keep in mind when youre considering cloud storage services. /slideshow/factors-to-keep-in-mind-when-youre-considering-cloud-storage-services/59428142 rkon-consequences-of-combining-160311153530
Cloud storage is a broad term. It can encompass anything from on premise solutions, to le storage, disaster recovery and off premise options. To narrow the scope, Ive dedicated the focus of todays discussion to the more popular cloud storage servicessuch as Dropbox, Box, OneDrivewhich are also known as hosted, off premise solutions.]]>
Cloud storage is a broad term. It can encompass anything from on premise solutions, to le storage, disaster recovery and off premise options. To narrow the scope, Ive dedicated the focus of todays discussion to the more popular cloud storage servicessuch as Dropbox, Box, OneDrivewhich are also known as hosted, off premise solutions.]]> Fri, 11 Mar 2016 15:35:30 GMT /slideshow/factors-to-keep-in-mind-when-youre-considering-cloud-storage-services/59428142 rpIBC@slideshare.net(rpIBC) Factors to keep in mind when youre considering cloud storage services. rpIBC Cloud storage is a broad term. It can encompass anything from on premise solutions, to le storage, disaster recovery and off premise options. To narrow the scope, Ive dedicated the focus of todays discussion to the more popular cloud storage servicessuch as Dropbox, Box, OneDrivewhich are also known as hosted, off premise solutions. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/rkon-consequences-of-combining-160311153530-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Cloud storage is a broad term. It can encompass anything from on premise solutions, to le storage, disaster recovery and off premise options. To narrow the scope, Ive dedicated the focus of todays discussion to the more popular cloud storage servicessuch as Dropbox, Box, OneDrivewhich are also known as hosted, off premise solutions.
Factors to keep in mind when youre considering cloud storage services. from Rita Barry
]]> 232 6 https://cdn.slidesharecdn.com/ss_thumbnails/rkon-consequences-of-combining-160311153530-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Why so many SIEM Implmentations Fail /rpIBC/why-so-many-siem-implmentations-fail rkon-why-seim-fails-160308163924
Unlike more tangible technologies where a failed implementation causes a down network, SIEM (security information and event management) requires a more qualitative approach to determining success or failure. The surprising reality is that most SIEM projects completely fail to deliver any discernable bene ts to the organization and are abandoned in frustration www.rkon.com]]>
Unlike more tangible technologies where a failed implementation causes a down network, SIEM (security information and event management) requires a more qualitative approach to determining success or failure. The surprising reality is that most SIEM projects completely fail to deliver any discernable bene ts to the organization and are abandoned in frustration www.rkon.com]]> Tue, 08 Mar 2016 16:39:24 GMT /rpIBC/why-so-many-siem-implmentations-fail rpIBC@slideshare.net(rpIBC) Why so many SIEM Implmentations Fail rpIBC Unlike more tangible technologies where a failed implementation causes a down network, SIEM (security information and event management) requires a more qualitative approach to determining success or failure. The surprising reality is that most SIEM projects completely fail to deliver any discernable bene ts to the organization and are abandoned in frustration www.rkon.com <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/rkon-why-seim-fails-160308163924-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Unlike more tangible technologies where a failed implementation causes a down network, SIEM (security information and event management) requires a more qualitative approach to determining success or failure. The surprising reality is that most SIEM projects completely fail to deliver any discernable bene ts to the organization and are abandoned in frustration www.rkon.com
Why so many SIEM Implmentations Fail from Rita Barry
]]> 784 5 https://cdn.slidesharecdn.com/ss_thumbnails/rkon-why-seim-fails-160308163924-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Carve-outs and Mergers and Acquisitions place unique demands on IT. How can you navigate all the complexities successfully? /slideshow/carveouts-and-mergers-and-acquisitions-place-unique-demands-on-it-how-can-you-navigate-all-the-complexities-successfully/58979857 rkon-capability-carve-outs-mergers-acquisitions-160302173838
Mergers are complex and Carve-outs only add to the dif culty and the level of complexity that the delivery team must manage. The creation of a stand-alone entity in a matter of weeks is daunting; moreover, the lack of cooperation from the legacy organization or the attrition of employees creates a chaotic environment that must be overcome. RKON helps clients to determine the most favorable level of IT sourcing and to implement the most appropriate technology for the new business unit all to ensure a successful day one. ]]>
Mergers are complex and Carve-outs only add to the dif culty and the level of complexity that the delivery team must manage. The creation of a stand-alone entity in a matter of weeks is daunting; moreover, the lack of cooperation from the legacy organization or the attrition of employees creates a chaotic environment that must be overcome. RKON helps clients to determine the most favorable level of IT sourcing and to implement the most appropriate technology for the new business unit all to ensure a successful day one. ]]> Wed, 02 Mar 2016 17:38:38 GMT /slideshow/carveouts-and-mergers-and-acquisitions-place-unique-demands-on-it-how-can-you-navigate-all-the-complexities-successfully/58979857 rpIBC@slideshare.net(rpIBC) Carve-outs and Mergers and Acquisitions place unique demands on IT. How can you navigate all the complexities successfully? rpIBC Mergers are complex and Carve-outs only add to the dif culty and the level of complexity that the delivery team must manage. The creation of a stand-alone entity in a matter of weeks is daunting; moreover, the lack of cooperation from the legacy organization or the attrition of employees creates a chaotic environment that must be overcome. RKON helps clients to determine the most favorable level of IT sourcing and to implement the most appropriate technology for the new business unit all to ensure a successful day one. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/rkon-capability-carve-outs-mergers-acquisitions-160302173838-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Mergers are complex and Carve-outs only add to the dif culty and the level of complexity that the delivery team must manage. The creation of a stand-alone entity in a matter of weeks is daunting; moreover, the lack of cooperation from the legacy organization or the attrition of employees creates a chaotic environment that must be overcome. RKON helps clients to determine the most favorable level of IT sourcing and to implement the most appropriate technology for the new business unit all to ensure a successful day one.
Carve-outs and Mergers and Acquisitions place unique demands on IT. How can you navigate all the complexities successfully? from Rita Barry
]]> 231 5 https://cdn.slidesharecdn.com/ss_thumbnails/rkon-capability-carve-outs-mergers-acquisitions-160302173838-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Hf asia15 /slideshow/hf-asia15/45682428 hf-asia15-150310184711-conversion-gate01
]]>
]]> Tue, 10 Mar 2015 18:47:10 GMT /slideshow/hf-asia15/45682428 rpIBC@slideshare.net(rpIBC) Hf asia15 rpIBC <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/hf-asia15-150310184711-conversion-gate01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Hf asia15 from Rita Barry
]]> 675 4 https://cdn.slidesharecdn.com/ss_thumbnails/hf-asia15-150310184711-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Tertiary Hospital Services 2015 /slideshow/tertiary-hospital-services-2015/45682385 ths15-150310184442-conversion-gate01
Tertiary Hospital Services Asia 2015, part of the Asia Healthcare Summit, will examine successful case studies on achieving top financially performing healthcare organizations whilst delivering quality tertiary healthcare services. Top Industry Issues to Be Discussed Include: Benchmarks and lessons from World Class Tertiary Hospitals Insights on clinical and operational excellence Investment in Tertiary Hospital Services and achieving financial success Streamlining outpatient services Advanced consultative care & remote monitoring of patient health Latest technology transforming patient accessibility, care and experiences Keynote representatives and decision makers from more than 15 public and private hospitals across the Asia Pacific region will convene and share their perspectives in developing world class tertiary hospital services, including: Chan Choo Lin, Director of Operations, Johns Hopkins, Singapore Dr. Alejandro C. Dizon, Chief Quality Officer, St. Luke's Medical Center, Philippines Alastair Mah, Chief Medical Officer, University Hospital Geelong & Barwon Health, Australia Haji Abdul Aziz Abdul Rahman, CEO, KPJ Penang Specialist Hospital, Malaysia Seemant Jauhari, CEO, Research & Innovations, Apollo Hospitals, India Nguyen Thi Le Thu, Marketing & Business Development Director, FV Hospital, Vietnam Grace Siew Wah Lim, Chief Financial Officer, KK Womans and Childrens Hospital, Singapore Andres M.Licaros, Jr., President & Chief Executive Officer, Asian Hospital and Medical Center, Philippines Michael Wong, CEO, Pantai Hospitals (Ayer Keroh), Malaysia David Sun, Consultant of Neurosurgery, Prince of Wales Hospital, Hong Kong Joe Hau, Director Corporate Services, Tan Tock Seng Hospital, Singapore Alan Young, Head of IT, Canossa Hospital (Caritas), Hong Kong Prof Kazuhiro Hara, President, Japanese Telemedicine and Telecare Association, Specially-appointed professor of Seto Inland Sea Regional Research Center, Kagawa University, Japan Chan Woo Kuk, Center for Future Innovation, Advisory Specialist, Samsung Medical Center, Korea http://www.tertiaryhospitalservices.com]]>
Tertiary Hospital Services Asia 2015, part of the Asia Healthcare Summit, will examine successful case studies on achieving top financially performing healthcare organizations whilst delivering quality tertiary healthcare services. Top Industry Issues to Be Discussed Include: Benchmarks and lessons from World Class Tertiary Hospitals Insights on clinical and operational excellence Investment in Tertiary Hospital Services and achieving financial success Streamlining outpatient services Advanced consultative care & remote monitoring of patient health Latest technology transforming patient accessibility, care and experiences Keynote representatives and decision makers from more than 15 public and private hospitals across the Asia Pacific region will convene and share their perspectives in developing world class tertiary hospital services, including: Chan Choo Lin, Director of Operations, Johns Hopkins, Singapore Dr. Alejandro C. Dizon, Chief Quality Officer, St. Luke's Medical Center, Philippines Alastair Mah, Chief Medical Officer, University Hospital Geelong & Barwon Health, Australia Haji Abdul Aziz Abdul Rahman, CEO, KPJ Penang Specialist Hospital, Malaysia Seemant Jauhari, CEO, Research & Innovations, Apollo Hospitals, India Nguyen Thi Le Thu, Marketing & Business Development Director, FV Hospital, Vietnam Grace Siew Wah Lim, Chief Financial Officer, KK Womans and Childrens Hospital, Singapore Andres M.Licaros, Jr., President & Chief Executive Officer, Asian Hospital and Medical Center, Philippines Michael Wong, CEO, Pantai Hospitals (Ayer Keroh), Malaysia David Sun, Consultant of Neurosurgery, Prince of Wales Hospital, Hong Kong Joe Hau, Director Corporate Services, Tan Tock Seng Hospital, Singapore Alan Young, Head of IT, Canossa Hospital (Caritas), Hong Kong Prof Kazuhiro Hara, President, Japanese Telemedicine and Telecare Association, Specially-appointed professor of Seto Inland Sea Regional Research Center, Kagawa University, Japan Chan Woo Kuk, Center for Future Innovation, Advisory Specialist, Samsung Medical Center, Korea http://www.tertiaryhospitalservices.com]]> Tue, 10 Mar 2015 18:44:41 GMT /slideshow/tertiary-hospital-services-2015/45682385 rpIBC@slideshare.net(rpIBC) Tertiary Hospital Services 2015 rpIBC Tertiary Hospital Services Asia 2015, part of the Asia Healthcare Summit, will examine successful case studies on achieving top financially performing healthcare organizations whilst delivering quality tertiary healthcare services. Top Industry Issues to Be Discussed Include: Benchmarks and lessons from World Class Tertiary Hospitals Insights on clinical and operational excellence Investment in Tertiary Hospital Services and achieving financial success Streamlining outpatient services Advanced consultative care & remote monitoring of patient health Latest technology transforming patient accessibility, care and experiences Keynote representatives and decision makers from more than 15 public and private hospitals across the Asia Pacific region will convene and share their perspectives in developing world class tertiary hospital services, including: Chan Choo Lin, Director of Operations, Johns Hopkins, Singapore Dr. Alejandro C. Dizon, Chief Quality Officer, St. Luke's Medical Center, Philippines Alastair Mah, Chief Medical Officer, University Hospital Geelong & Barwon Health, Australia Haji Abdul Aziz Abdul Rahman, CEO, KPJ Penang Specialist Hospital, Malaysia Seemant Jauhari, CEO, Research & Innovations, Apollo Hospitals, India Nguyen Thi Le Thu, Marketing & Business Development Director, FV Hospital, Vietnam Grace Siew Wah Lim, Chief Financial Officer, KK Womans and Childrens Hospital, Singapore Andres M.Licaros, Jr., President & Chief Executive Officer, Asian Hospital and Medical Center, Philippines Michael Wong, CEO, Pantai Hospitals (Ayer Keroh), Malaysia David Sun, Consultant of Neurosurgery, Prince of Wales Hospital, Hong Kong Joe Hau, Director Corporate Services, Tan Tock Seng Hospital, Singapore Alan Young, Head of IT, Canossa Hospital (Caritas), Hong Kong Prof Kazuhiro Hara, President, Japanese Telemedicine and Telecare Association, Specially-appointed professor of Seto Inland Sea Regional Research Center, Kagawa University, Japan Chan Woo Kuk, Center for Future Innovation, Advisory Specialist, Samsung Medical Center, Korea http://www.tertiaryhospitalservices.com <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ths15-150310184442-conversion-gate01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Tertiary Hospital Services Asia 2015, part of the Asia Healthcare Summit, will examine successful case studies on achieving top financially performing healthcare organizations whilst delivering quality tertiary healthcare services. Top Industry Issues to Be Discussed Include: Benchmarks and lessons from World Class Tertiary Hospitals Insights on clinical and operational excellence Investment in Tertiary Hospital Services and achieving financial success Streamlining outpatient services Advanced consultative care &amp; remote monitoring of patient health Latest technology transforming patient accessibility, care and experiences Keynote representatives and decision makers from more than 15 public and private hospitals across the Asia Pacific region will convene and share their perspectives in developing world class tertiary hospital services, including: Chan Choo Lin, Director of Operations, Johns Hopkins, Singapore Dr. Alejandro C. Dizon, Chief Quality Officer, St. Luke&#39;s Medical Center, Philippines Alastair Mah, Chief Medical Officer, University Hospital Geelong &amp; Barwon Health, Australia Haji Abdul Aziz Abdul Rahman, CEO, KPJ Penang Specialist Hospital, Malaysia Seemant Jauhari, CEO, Research &amp; Innovations, Apollo Hospitals, India Nguyen Thi Le Thu, Marketing &amp; Business Development Director, FV Hospital, Vietnam Grace Siew Wah Lim, Chief Financial Officer, KK Womans and Childrens Hospital, Singapore Andres M.Licaros, Jr., President &amp; Chief Executive Officer, Asian Hospital and Medical Center, Philippines Michael Wong, CEO, Pantai Hospitals (Ayer Keroh), Malaysia David Sun, Consultant of Neurosurgery, Prince of Wales Hospital, Hong Kong Joe Hau, Director Corporate Services, Tan Tock Seng Hospital, Singapore Alan Young, Head of IT, Canossa Hospital (Caritas), Hong Kong Prof Kazuhiro Hara, President, Japanese Telemedicine and Telecare Association, Specially-appointed professor of Seto Inland Sea Regional Research Center, Kagawa University, Japan Chan Woo Kuk, Center for Future Innovation, Advisory Specialist, Samsung Medical Center, Korea http://www.tertiaryhospitalservices.com
Tertiary Hospital Services 2015 from Rita Barry
]]> 1625 10 https://cdn.slidesharecdn.com/ss_thumbnails/ths15-150310184442-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Biopharma Production & Development Week 2015 /slideshow/bdpweek15-conf/44189873 bdpweek15conf-150202220812-conversion-gate01
Whats New for 2015 - C-Level Panel: Cutting Edge Insights on Chinas Growing Biotech Market - China FDA Special Address - 80+ Key Expert Speakers from Asias leading Pharma & Biotech - 1 Joint Exhibition & Networking Area - 4 Days of Expert Knowledge Sharing - Revamped Program with New Special Focused Tracks & Sessions]]>
Whats New for 2015 - C-Level Panel: Cutting Edge Insights on Chinas Growing Biotech Market - China FDA Special Address - 80+ Key Expert Speakers from Asias leading Pharma & Biotech - 1 Joint Exhibition & Networking Area - 4 Days of Expert Knowledge Sharing - Revamped Program with New Special Focused Tracks & Sessions]]> Mon, 02 Feb 2015 22:08:12 GMT /slideshow/bdpweek15-conf/44189873 rpIBC@slideshare.net(rpIBC) Biopharma Production & Development Week 2015 rpIBC Whats New for 2015 - C-Level Panel: Cutting Edge Insights on Chinas Growing Biotech Market - China FDA Special Address - 80+ Key Expert Speakers from Asias leading Pharma & Biotech - 1 Joint Exhibition & Networking Area - 4 Days of Expert Knowledge Sharing - Revamped Program with New Special Focused Tracks & Sessions <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bdpweek15conf-150202220812-conversion-gate01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Whats New for 2015 - C-Level Panel: Cutting Edge Insights on Chinas Growing Biotech Market - China FDA Special Address - 80+ Key Expert Speakers from Asias leading Pharma &amp; Biotech - 1 Joint Exhibition &amp; Networking Area - 4 Days of Expert Knowledge Sharing - Revamped Program with New Special Focused Tracks &amp; Sessions
Biopharma Production & Development Week 2015 from Rita Barry
]]> 1497 3 https://cdn.slidesharecdn.com/ss_thumbnails/bdpweek15conf-150202220812-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Cell Line Development and Engineering 2015 /slideshow/4th-cellline2015/44189664 4thcellline2015-150202215822-conversion-gate01
The 4th Annual Cell Line Development & Engineering Asia conference is a must attend event for you to get the latest updates and best practices in Cell Line Generation, Bioprocessing and Antibodies Development! This exclusive forum is where industry experts will share lessons learned through case studies, strategic discussion groups and interactive roundtables to collectively collaborate and provide solutions to your most pressing challenges. Bring back new ideas to do better business! 4 Reasons Why You Must Attend this 2015 1. Update yourself with latest technologies to accelerate every stage of cell line development with maximum efficiency, quality and reduced cost 2. Enhance cell line generation in the early stages with best practices in transfection, optimizing cell culture media, and implement advancements in clone screening and selection techniques 3. Gain effective bioprocess control & optimization strategies, for efficient, safe and cost effective scale-up 4. Latest cutting edge updates on antibody development- novel screening strategies for target discovery, challenges in ADCs, engineering bispecifics and boosting efficacy in antibody therapeutics http://www.celllineasia.com]]>
The 4th Annual Cell Line Development & Engineering Asia conference is a must attend event for you to get the latest updates and best practices in Cell Line Generation, Bioprocessing and Antibodies Development! This exclusive forum is where industry experts will share lessons learned through case studies, strategic discussion groups and interactive roundtables to collectively collaborate and provide solutions to your most pressing challenges. Bring back new ideas to do better business! 4 Reasons Why You Must Attend this 2015 1. Update yourself with latest technologies to accelerate every stage of cell line development with maximum efficiency, quality and reduced cost 2. Enhance cell line generation in the early stages with best practices in transfection, optimizing cell culture media, and implement advancements in clone screening and selection techniques 3. Gain effective bioprocess control & optimization strategies, for efficient, safe and cost effective scale-up 4. Latest cutting edge updates on antibody development- novel screening strategies for target discovery, challenges in ADCs, engineering bispecifics and boosting efficacy in antibody therapeutics http://www.celllineasia.com]]> Mon, 02 Feb 2015 21:58:21 GMT /slideshow/4th-cellline2015/44189664 rpIBC@slideshare.net(rpIBC) Cell Line Development and Engineering 2015 rpIBC The 4th Annual Cell Line Development & Engineering Asia conference is a must attend event for you to get the latest updates and best practices in Cell Line Generation, Bioprocessing and Antibodies Development! This exclusive forum is where industry experts will share lessons learned through case studies, strategic discussion groups and interactive roundtables to collectively collaborate and provide solutions to your most pressing challenges. Bring back new ideas to do better business! 4 Reasons Why You Must Attend this 2015 1. Update yourself with latest technologies to accelerate every stage of cell line development with maximum efficiency, quality and reduced cost 2. Enhance cell line generation in the early stages with best practices in transfection, optimizing cell culture media, and implement advancements in clone screening and selection techniques 3. Gain effective bioprocess control & optimization strategies, for efficient, safe and cost effective scale-up 4. Latest cutting edge updates on antibody development- novel screening strategies for target discovery, challenges in ADCs, engineering bispecifics and boosting efficacy in antibody therapeutics http://www.celllineasia.com <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/4thcellline2015-150202215822-conversion-gate01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> The 4th Annual Cell Line Development &amp; Engineering Asia conference is a must attend event for you to get the latest updates and best practices in Cell Line Generation, Bioprocessing and Antibodies Development! This exclusive forum is where industry experts will share lessons learned through case studies, strategic discussion groups and interactive roundtables to collectively collaborate and provide solutions to your most pressing challenges. Bring back new ideas to do better business! 4 Reasons Why You Must Attend this 2015 1. Update yourself with latest technologies to accelerate every stage of cell line development with maximum efficiency, quality and reduced cost 2. Enhance cell line generation in the early stages with best practices in transfection, optimizing cell culture media, and implement advancements in clone screening and selection techniques 3. Gain effective bioprocess control &amp; optimization strategies, for efficient, safe and cost effective scale-up 4. Latest cutting edge updates on antibody development- novel screening strategies for target discovery, challenges in ADCs, engineering bispecifics and boosting efficacy in antibody therapeutics http://www.celllineasia.com
Cell Line Development and Engineering 2015 from Rita Barry
]]> 1207 3 https://cdn.slidesharecdn.com/ss_thumbnails/4thcellline2015-150202215822-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Biosimilars Asia 2015 /rpIBC/6th-biosimilars2015 6thbiosimilars2015-150202190428-conversion-gate02
Whats NEW in 2015s program? More case studies on successful commercialization Insights on developing biosimilars under new CFDA guideline Emerging business models in regulated and developing markets New and timely topics on: o Valuating biosimilars investments o Successful technology transfer o Key criteria in gaining approval Also, NEW Expert Faculty includes: Dr Shin Jae Chang, Vice President, Celltrion, Korea Ira Jacobs, Global Oncology Lead, Biosimilars, Pfizer, US Paul Thomas, Business Unit Head Biosimilars, Biocon, India Dr. Martina A. Sersch, Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead, Genentech, Inc. / F. Hoffmann-La Roche Ltd. Raj Kannan, Vice President, Commercial Head, Biosimilars, Merck, Switzerland Huiguo (Forrest) Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co., Ltd, China Ko Chung Lin, Chief Executive Officer, PharmaEssentia Corporation, Taiwan Wen Yong, Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu AoSaiKang Pharmaceutical Co Ltd, China http://www.biosimilarsasia.com]]>
Whats NEW in 2015s program? More case studies on successful commercialization Insights on developing biosimilars under new CFDA guideline Emerging business models in regulated and developing markets New and timely topics on: o Valuating biosimilars investments o Successful technology transfer o Key criteria in gaining approval Also, NEW Expert Faculty includes: Dr Shin Jae Chang, Vice President, Celltrion, Korea Ira Jacobs, Global Oncology Lead, Biosimilars, Pfizer, US Paul Thomas, Business Unit Head Biosimilars, Biocon, India Dr. Martina A. Sersch, Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead, Genentech, Inc. / F. Hoffmann-La Roche Ltd. Raj Kannan, Vice President, Commercial Head, Biosimilars, Merck, Switzerland Huiguo (Forrest) Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co., Ltd, China Ko Chung Lin, Chief Executive Officer, PharmaEssentia Corporation, Taiwan Wen Yong, Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu AoSaiKang Pharmaceutical Co Ltd, China http://www.biosimilarsasia.com]]> Mon, 02 Feb 2015 19:04:28 GMT /rpIBC/6th-biosimilars2015 rpIBC@slideshare.net(rpIBC) Biosimilars Asia 2015 rpIBC Whats NEW in 2015s program? More case studies on successful commercialization Insights on developing biosimilars under new CFDA guideline Emerging business models in regulated and developing markets New and timely topics on: o Valuating biosimilars investments o Successful technology transfer o Key criteria in gaining approval Also, NEW Expert Faculty includes: Dr Shin Jae Chang, Vice President, Celltrion, Korea Ira Jacobs, Global Oncology Lead, Biosimilars, Pfizer, US Paul Thomas, Business Unit Head Biosimilars, Biocon, India Dr. Martina A. Sersch, Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead, Genentech, Inc. / F. Hoffmann-La Roche Ltd. Raj Kannan, Vice President, Commercial Head, Biosimilars, Merck, Switzerland Huiguo (Forrest) Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co., Ltd, China Ko Chung Lin, Chief Executive Officer, PharmaEssentia Corporation, Taiwan Wen Yong, Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu AoSaiKang Pharmaceutical Co Ltd, China http://www.biosimilarsasia.com <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/6thbiosimilars2015-150202190428-conversion-gate02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Whats NEW in 2015s program? More case studies on successful commercialization Insights on developing biosimilars under new CFDA guideline Emerging business models in regulated and developing markets New and timely topics on: o Valuating biosimilars investments o Successful technology transfer o Key criteria in gaining approval Also, NEW Expert Faculty includes: Dr Shin Jae Chang, Vice President, Celltrion, Korea Ira Jacobs, Global Oncology Lead, Biosimilars, Pfizer, US Paul Thomas, Business Unit Head Biosimilars, Biocon, India Dr. Martina A. Sersch, Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead, Genentech, Inc. / F. Hoffmann-La Roche Ltd. Raj Kannan, Vice President, Commercial Head, Biosimilars, Merck, Switzerland Huiguo (Forrest) Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co., Ltd, China Ko Chung Lin, Chief Executive Officer, PharmaEssentia Corporation, Taiwan Wen Yong, Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu AoSaiKang Pharmaceutical Co Ltd, China http://www.biosimilarsasia.com
Biosimilars Asia 2015 from Rita Barry
]]> 825 4 https://cdn.slidesharecdn.com/ss_thumbnails/6thbiosimilars2015-150202190428-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 5th Annual BioManufacturing Asia 2015 /slideshow/5th-biom2015/43769724 5thbiom2015-150122010447-conversion-gate01
A key source of growth in biologics over the next several years will be Biomanufacturing Ge Li, Chairman and CEO, Wuxi &lt;outsourcing-pharma.com,> Other issues with single-use include standardization of systems, the dependability to vendors, and the supply chain and waste management but if we can overcome extractables and leachables, we will eventually be able to scale up to many thousands of liters. Jason Li, Senior Director, Downstream Processing, Genor Biopharma &lt;biopharma-reporter.com,> Industry experts will discuss these and more at the 5th Annual Biomanufacturing Conference in Grand Hyatt Shanghai, China on 19 22 May 2015 during IBCs Biopharma Development & Production (BDP) Week.]]>
A key source of growth in biologics over the next several years will be Biomanufacturing Ge Li, Chairman and CEO, Wuxi &lt;outsourcing-pharma.com,> Other issues with single-use include standardization of systems, the dependability to vendors, and the supply chain and waste management but if we can overcome extractables and leachables, we will eventually be able to scale up to many thousands of liters. Jason Li, Senior Director, Downstream Processing, Genor Biopharma &lt;biopharma-reporter.com,> Industry experts will discuss these and more at the 5th Annual Biomanufacturing Conference in Grand Hyatt Shanghai, China on 19 22 May 2015 during IBCs Biopharma Development & Production (BDP) Week.]]> Thu, 22 Jan 2015 01:04:47 GMT /slideshow/5th-biom2015/43769724 rpIBC@slideshare.net(rpIBC) 5th Annual BioManufacturing Asia 2015 rpIBC A key source of growth in biologics over the next several years will be Biomanufacturing Ge Li, Chairman and CEO, Wuxi &lt;outsourcing-pharma.com,> Other issues with single-use include standardization of systems, the dependability to vendors, and the supply chain and waste management but if we can overcome extractables and leachables, we will eventually be able to scale up to many thousands of liters. Jason Li, Senior Director, Downstream Processing, Genor Biopharma &lt;biopharma-reporter.com,> Industry experts will discuss these and more at the 5th Annual Biomanufacturing Conference in Grand Hyatt Shanghai, China on 19 22 May 2015 during IBCs Biopharma Development & Production (BDP) Week. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/5thbiom2015-150122010447-conversion-gate01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> A key source of growth in biologics over the next several years will be Biomanufacturing Ge Li, Chairman and CEO, Wuxi &amp;lt;outsourcing-pharma.com,&gt; Other issues with single-use include standardization of systems, the dependability to vendors, and the supply chain and waste management but if we can overcome extractables and leachables, we will eventually be able to scale up to many thousands of liters. Jason Li, Senior Director, Downstream Processing, Genor Biopharma &amp;lt;biopharma-reporter.com,&gt; Industry experts will discuss these and more at the 5th Annual Biomanufacturing Conference in Grand Hyatt Shanghai, China on 19 22 May 2015 during IBCs Biopharma Development &amp; Production (BDP) Week.
5th Annual BioManufacturing Asia 2015 from Rita Barry
]]> 724 4 https://cdn.slidesharecdn.com/ss_thumbnails/5thbiom2015-150122010447-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Pharmaceutical Compliance 2015 /slideshow/pharma-compliance/43769538 pharmacompliance-150122005524-conversion-gate01
As you know, pharma compliance is a critical issue, particularly in China. The Chinese governments recent crackdowns on the business practices of various pharmaceutical companies have sent shockwaves throughout the industry and the price to pay for non-compliance is exceedingly high, with massive revenue losses and irreclaimable reputational damages To address this pertinent issue, IBC Asia is convening the forthcoming Pharma Compliance Summit (Mar 2015) in Shanghai, China. Set to be an informative and insightful event, this conference will prepare participants in dealing with the latest legal compliance landmines and equip them with an in-depth understanding of how to mitigate non- compliance risks at every part of the pharma value chain. Top companies will share best practices of internal compliance programs and third party due diligence strategies; Gain these exclusive insights and incorporate them into their own company, reaping maximum benefits. Your expert speaker faculty includes: Leon Wang, Vice President, AstraZeneca China Heike Deters, Head of Compliance, Bayer Healthcare China Dr Wang Xianlin, Member, Expert Advisory Group of Anti-Monopoly Commission, State Council Peoples Republic of China Maija Burtmanis, Regional Legal & Compliance Director JAPAC, AbbVie Gareth Lee, General Counsel & Head of Compliance APAC, Allergan Cristopher Landrito, Regional Compliance Manager APAC, Merck David Shen, General Counsel & VP Legal, AstraZeneca China Dr Wu Ke, President, Shanghai BravoBio Alejandro Castro, Regional Audit Manager Asia Pacific, Novartis Linda Ling, Senior Healthcare Compliance Manager, OTC China, Johnson & Johnson http://www.pharmacompliance-china.com]]>
As you know, pharma compliance is a critical issue, particularly in China. The Chinese governments recent crackdowns on the business practices of various pharmaceutical companies have sent shockwaves throughout the industry and the price to pay for non-compliance is exceedingly high, with massive revenue losses and irreclaimable reputational damages To address this pertinent issue, IBC Asia is convening the forthcoming Pharma Compliance Summit (Mar 2015) in Shanghai, China. Set to be an informative and insightful event, this conference will prepare participants in dealing with the latest legal compliance landmines and equip them with an in-depth understanding of how to mitigate non- compliance risks at every part of the pharma value chain. Top companies will share best practices of internal compliance programs and third party due diligence strategies; Gain these exclusive insights and incorporate them into their own company, reaping maximum benefits. Your expert speaker faculty includes: Leon Wang, Vice President, AstraZeneca China Heike Deters, Head of Compliance, Bayer Healthcare China Dr Wang Xianlin, Member, Expert Advisory Group of Anti-Monopoly Commission, State Council Peoples Republic of China Maija Burtmanis, Regional Legal & Compliance Director JAPAC, AbbVie Gareth Lee, General Counsel & Head of Compliance APAC, Allergan Cristopher Landrito, Regional Compliance Manager APAC, Merck David Shen, General Counsel & VP Legal, AstraZeneca China Dr Wu Ke, President, Shanghai BravoBio Alejandro Castro, Regional Audit Manager Asia Pacific, Novartis Linda Ling, Senior Healthcare Compliance Manager, OTC China, Johnson & Johnson http://www.pharmacompliance-china.com]]> Thu, 22 Jan 2015 00:55:24 GMT /slideshow/pharma-compliance/43769538 rpIBC@slideshare.net(rpIBC) Pharmaceutical Compliance 2015 rpIBC As you know, pharma compliance is a critical issue, particularly in China. The Chinese governments recent crackdowns on the business practices of various pharmaceutical companies have sent shockwaves throughout the industry and the price to pay for non-compliance is exceedingly high, with massive revenue losses and irreclaimable reputational damages To address this pertinent issue, IBC Asia is convening the forthcoming Pharma Compliance Summit (Mar 2015) in Shanghai, China. Set to be an informative and insightful event, this conference will prepare participants in dealing with the latest legal compliance landmines and equip them with an in-depth understanding of how to mitigate non- compliance risks at every part of the pharma value chain. Top companies will share best practices of internal compliance programs and third party due diligence strategies; Gain these exclusive insights and incorporate them into their own company, reaping maximum benefits. Your expert speaker faculty includes: Leon Wang, Vice President, AstraZeneca China Heike Deters, Head of Compliance, Bayer Healthcare China Dr Wang Xianlin, Member, Expert Advisory Group of Anti-Monopoly Commission, State Council Peoples Republic of China Maija Burtmanis, Regional Legal & Compliance Director JAPAC, AbbVie Gareth Lee, General Counsel & Head of Compliance APAC, Allergan Cristopher Landrito, Regional Compliance Manager APAC, Merck David Shen, General Counsel & VP Legal, AstraZeneca China Dr Wu Ke, President, Shanghai BravoBio Alejandro Castro, Regional Audit Manager Asia Pacific, Novartis Linda Ling, Senior Healthcare Compliance Manager, OTC China, Johnson & Johnson http://www.pharmacompliance-china.com <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pharmacompliance-150122005524-conversion-gate01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> As you know, pharma compliance is a critical issue, particularly in China. The Chinese governments recent crackdowns on the business practices of various pharmaceutical companies have sent shockwaves throughout the industry and the price to pay for non-compliance is exceedingly high, with massive revenue losses and irreclaimable reputational damages To address this pertinent issue, IBC Asia is convening the forthcoming Pharma Compliance Summit (Mar 2015) in Shanghai, China. Set to be an informative and insightful event, this conference will prepare participants in dealing with the latest legal compliance landmines and equip them with an in-depth understanding of how to mitigate non- compliance risks at every part of the pharma value chain. Top companies will share best practices of internal compliance programs and third party due diligence strategies; Gain these exclusive insights and incorporate them into their own company, reaping maximum benefits. Your expert speaker faculty includes: Leon Wang, Vice President, AstraZeneca China Heike Deters, Head of Compliance, Bayer Healthcare China Dr Wang Xianlin, Member, Expert Advisory Group of Anti-Monopoly Commission, State Council Peoples Republic of China Maija Burtmanis, Regional Legal &amp; Compliance Director JAPAC, AbbVie Gareth Lee, General Counsel &amp; Head of Compliance APAC, Allergan Cristopher Landrito, Regional Compliance Manager APAC, Merck David Shen, General Counsel &amp; VP Legal, AstraZeneca China Dr Wu Ke, President, Shanghai BravoBio Alejandro Castro, Regional Audit Manager Asia Pacific, Novartis Linda Ling, Senior Healthcare Compliance Manager, OTC China, Johnson &amp; Johnson http://www.pharmacompliance-china.com
Pharmaceutical Compliance 2015 from Rita Barry
]]> 1459 1 https://cdn.slidesharecdn.com/ss_thumbnails/pharmacompliance-150122005524-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 OTC Pharma Asia 2015 /slideshow/otc-pharma-asia-2015/43769427 5thotcpharma-latestbrochure-150122005031-conversion-gate02
IBCs OTC Pharma Asia conference is returning 2-5 March 2015 at Grand Copthorne Waterfront Hotel, Singapore to prepare you for future growth in the OTC and Consumer Health market in Asia. You will witness how the OTC landscape varies by country as well as the latest product trends, consumer insights and innovative offerings in OTC a crucial element to achieve global success. http://www.otcpharmaasia.com]]>
IBCs OTC Pharma Asia conference is returning 2-5 March 2015 at Grand Copthorne Waterfront Hotel, Singapore to prepare you for future growth in the OTC and Consumer Health market in Asia. You will witness how the OTC landscape varies by country as well as the latest product trends, consumer insights and innovative offerings in OTC a crucial element to achieve global success. http://www.otcpharmaasia.com]]> Thu, 22 Jan 2015 00:50:30 GMT /slideshow/otc-pharma-asia-2015/43769427 rpIBC@slideshare.net(rpIBC) OTC Pharma Asia 2015 rpIBC IBCs OTC Pharma Asia conference is returning 2-5 March 2015 at Grand Copthorne Waterfront Hotel, Singapore to prepare you for future growth in the OTC and Consumer Health market in Asia. You will witness how the OTC landscape varies by country as well as the latest product trends, consumer insights and innovative offerings in OTC a crucial element to achieve global success. http://www.otcpharmaasia.com <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/5thotcpharma-latestbrochure-150122005031-conversion-gate02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> IBCs OTC Pharma Asia conference is returning 2-5 March 2015 at Grand Copthorne Waterfront Hotel, Singapore to prepare you for future growth in the OTC and Consumer Health market in Asia. You will witness how the OTC landscape varies by country as well as the latest product trends, consumer insights and innovative offerings in OTC a crucial element to achieve global success. http://www.otcpharmaasia.com
OTC Pharma Asia 2015 from Rita Barry
]]> 1923 6 https://cdn.slidesharecdn.com/ss_thumbnails/5thotcpharma-latestbrochure-150122005031-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Philippines healthcare 2015 /slideshow/philippines-healthcare-2015/42379207 philippineshealthcare-141204232309-conversion-gate01
The inaugural Philippines Healthcare will focus on investment opportunities in the Philippines healthcare sector as well as examine the developments in healthcare plans and policies by government, market access opportunities for pharma and technology, new healthcare facility projects, upgrades and expansions and increasing efficiencies of existing facilities. Philippines is currently focused on speeding up health facilities and upgrades, meeting the needs and growing demand for health specialists, training to ensure competency and quality of healthcare services and ensuring the availability of drugs throughout the country. The conference will have discussions on policy and regulation updates, investment opportunities, projects and developments to strengthen Philippines healthcare infrastructure and delivery. It will be held in Manila and will have representations from government, hospitals, insurance companies, pharma companies, health technology and medical device providers and other related stakeholders.]]>
The inaugural Philippines Healthcare will focus on investment opportunities in the Philippines healthcare sector as well as examine the developments in healthcare plans and policies by government, market access opportunities for pharma and technology, new healthcare facility projects, upgrades and expansions and increasing efficiencies of existing facilities. Philippines is currently focused on speeding up health facilities and upgrades, meeting the needs and growing demand for health specialists, training to ensure competency and quality of healthcare services and ensuring the availability of drugs throughout the country. The conference will have discussions on policy and regulation updates, investment opportunities, projects and developments to strengthen Philippines healthcare infrastructure and delivery. It will be held in Manila and will have representations from government, hospitals, insurance companies, pharma companies, health technology and medical device providers and other related stakeholders.]]> Thu, 04 Dec 2014 23:23:09 GMT /slideshow/philippines-healthcare-2015/42379207 rpIBC@slideshare.net(rpIBC) Philippines healthcare 2015 rpIBC The inaugural Philippines Healthcare will focus on investment opportunities in the Philippines healthcare sector as well as examine the developments in healthcare plans and policies by government, market access opportunities for pharma and technology, new healthcare facility projects, upgrades and expansions and increasing efficiencies of existing facilities. Philippines is currently focused on speeding up health facilities and upgrades, meeting the needs and growing demand for health specialists, training to ensure competency and quality of healthcare services and ensuring the availability of drugs throughout the country. The conference will have discussions on policy and regulation updates, investment opportunities, projects and developments to strengthen Philippines healthcare infrastructure and delivery. It will be held in Manila and will have representations from government, hospitals, insurance companies, pharma companies, health technology and medical device providers and other related stakeholders. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/philippineshealthcare-141204232309-conversion-gate01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> The inaugural Philippines Healthcare will focus on investment opportunities in the Philippines healthcare sector as well as examine the developments in healthcare plans and policies by government, market access opportunities for pharma and technology, new healthcare facility projects, upgrades and expansions and increasing efficiencies of existing facilities. Philippines is currently focused on speeding up health facilities and upgrades, meeting the needs and growing demand for health specialists, training to ensure competency and quality of healthcare services and ensuring the availability of drugs throughout the country. The conference will have discussions on policy and regulation updates, investment opportunities, projects and developments to strengthen Philippines healthcare infrastructure and delivery. It will be held in Manila and will have representations from government, hospitals, insurance companies, pharma companies, health technology and medical device providers and other related stakeholders.
Philippines healthcare 2015 from Rita Barry
]]> 7345 6 https://cdn.slidesharecdn.com/ss_thumbnails/philippineshealthcare-141204232309-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 9th Clearing, Settlement Custody Asia /slideshow/9th-csc-2/41982043 9thcsc2-141124220316-conversion-gate02
For 2015, we are going to hear NEW panel speakers from Indonesia Stock Exchange, Australia Stock Exchange, Philippine Stock Exchange, Tokyo Stock Exchange, Osaka Stock Exchange and Colombo Stock Exchange. Each of the exchanges will present a 10 minute update about their country on what are the new initiatives that have rolled out, how they address the needs of the private side, which infrastructure support the local regulatory body address in the short term vs. long term and the ASEAN trading link to ease cross border trading. Not only that, we will answer key questions of the post trade industry including: Have Asian market participants been preparing for operational readiness as Dodd Frank, Emir and Basel 3 are being unrolled in Asia? Will T2S lead to a migration of all financial players to ISO 20022 in Europe? What are the impacts of Hong Kong Shanghai Stock Connect on Asias economy and the global financial markets? What is the impact on transaction funding and foreign exchange operations of moving from T+3 to T+2? Are CCPs all equal? Can we quantify the benefits of moving to a CCP? How is the buyside firm in Asia dealing with a collateral solution? Do the costs outweigh the benefits? ]]>
For 2015, we are going to hear NEW panel speakers from Indonesia Stock Exchange, Australia Stock Exchange, Philippine Stock Exchange, Tokyo Stock Exchange, Osaka Stock Exchange and Colombo Stock Exchange. Each of the exchanges will present a 10 minute update about their country on what are the new initiatives that have rolled out, how they address the needs of the private side, which infrastructure support the local regulatory body address in the short term vs. long term and the ASEAN trading link to ease cross border trading. Not only that, we will answer key questions of the post trade industry including: Have Asian market participants been preparing for operational readiness as Dodd Frank, Emir and Basel 3 are being unrolled in Asia? Will T2S lead to a migration of all financial players to ISO 20022 in Europe? What are the impacts of Hong Kong Shanghai Stock Connect on Asias economy and the global financial markets? What is the impact on transaction funding and foreign exchange operations of moving from T+3 to T+2? Are CCPs all equal? Can we quantify the benefits of moving to a CCP? How is the buyside firm in Asia dealing with a collateral solution? Do the costs outweigh the benefits? ]]> Mon, 24 Nov 2014 22:03:16 GMT /slideshow/9th-csc-2/41982043 rpIBC@slideshare.net(rpIBC) 9th Clearing, Settlement Custody Asia rpIBC For 2015, we are going to hear NEW panel speakers from Indonesia Stock Exchange, Australia Stock Exchange, Philippine Stock Exchange, Tokyo Stock Exchange, Osaka Stock Exchange and Colombo Stock Exchange. Each of the exchanges will present a 10 minute update about their country on what are the new initiatives that have rolled out, how they address the needs of the private side, which infrastructure support the local regulatory body address in the short term vs. long term and the ASEAN trading link to ease cross border trading. Not only that, we will answer key questions of the post trade industry including: Have Asian market participants been preparing for operational readiness as Dodd Frank, Emir and Basel 3 are being unrolled in Asia? Will T2S lead to a migration of all financial players to ISO 20022 in Europe? What are the impacts of Hong Kong Shanghai Stock Connect on Asias economy and the global financial markets? What is the impact on transaction funding and foreign exchange operations of moving from T+3 to T+2? Are CCPs all equal? Can we quantify the benefits of moving to a CCP? How is the buyside firm in Asia dealing with a collateral solution? Do the costs outweigh the benefits? <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/9thcsc2-141124220316-conversion-gate02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> For 2015, we are going to hear NEW panel speakers from Indonesia Stock Exchange, Australia Stock Exchange, Philippine Stock Exchange, Tokyo Stock Exchange, Osaka Stock Exchange and Colombo Stock Exchange. Each of the exchanges will present a 10 minute update about their country on what are the new initiatives that have rolled out, how they address the needs of the private side, which infrastructure support the local regulatory body address in the short term vs. long term and the ASEAN trading link to ease cross border trading. Not only that, we will answer key questions of the post trade industry including: Have Asian market participants been preparing for operational readiness as Dodd Frank, Emir and Basel 3 are being unrolled in Asia? Will T2S lead to a migration of all financial players to ISO 20022 in Europe? What are the impacts of Hong Kong Shanghai Stock Connect on Asias economy and the global financial markets? What is the impact on transaction funding and foreign exchange operations of moving from T+3 to T+2? Are CCPs all equal? Can we quantify the benefits of moving to a CCP? How is the buyside firm in Asia dealing with a collateral solution? Do the costs outweigh the benefits?
9th Clearing, Settlement Custody Asia from Rita Barry
]]> 1100 5 https://cdn.slidesharecdn.com/ss_thumbnails/9thcsc2-141124220316-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds document White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Biopharma Production and Development China 2015 /slideshow/bdpweek2015/40950668 bdpweek2015-141031015402-conversion-gate01
As the BioPharma industry grows in China and the Asian region, we invite you to be a part of this tremendous growth & development opportunities! IBCs Biopharma Development & Production Week in China is THE meeting place for biopharma industry professionals and scientists to get the highest quality and practical information that will enable them to develop competitive advantages and advance their capabilities in developing and manufacturing cell lines, biosimilars, biobetters, vaccines or novel biologics. Top Reasons Why You Should Participate: - Establish Business Partnerships with Chinese/Asian drug developers and contract manufacturers - Learn technical & practical know how from experiences on the ground in Asia - Showcase your cutting edge solutions in front of key China/Asian Biopharma decision makers http://www.biopharmaproduction.com]]>
As the BioPharma industry grows in China and the Asian region, we invite you to be a part of this tremendous growth & development opportunities! IBCs Biopharma Development & Production Week in China is THE meeting place for biopharma industry professionals and scientists to get the highest quality and practical information that will enable them to develop competitive advantages and advance their capabilities in developing and manufacturing cell lines, biosimilars, biobetters, vaccines or novel biologics. Top Reasons Why You Should Participate: - Establish Business Partnerships with Chinese/Asian drug developers and contract manufacturers - Learn technical & practical know how from experiences on the ground in Asia - Showcase your cutting edge solutions in front of key China/Asian Biopharma decision makers http://www.biopharmaproduction.com]]> Fri, 31 Oct 2014 01:54:02 GMT /slideshow/bdpweek2015/40950668 rpIBC@slideshare.net(rpIBC) Biopharma Production and Development China 2015 rpIBC As the BioPharma industry grows in China and the Asian region, we invite you to be a part of this tremendous growth & development opportunities! IBCs Biopharma Development & Production Week in China is THE meeting place for biopharma industry professionals and scientists to get the highest quality and practical information that will enable them to develop competitive advantages and advance their capabilities in developing and manufacturing cell lines, biosimilars, biobetters, vaccines or novel biologics. Top Reasons Why You Should Participate: - Establish Business Partnerships with Chinese/Asian drug developers and contract manufacturers - Learn technical & practical know how from experiences on the ground in Asia - Showcase your cutting edge solutions in front of key China/Asian Biopharma decision makers http://www.biopharmaproduction.com <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bdpweek2015-141031015402-conversion-gate01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> As the BioPharma industry grows in China and the Asian region, we invite you to be a part of this tremendous growth &amp; development opportunities! IBCs Biopharma Development &amp; Production Week in China is THE meeting place for biopharma industry professionals and scientists to get the highest quality and practical information that will enable them to develop competitive advantages and advance their capabilities in developing and manufacturing cell lines, biosimilars, biobetters, vaccines or novel biologics. Top Reasons Why You Should Participate: - Establish Business Partnerships with Chinese/Asian drug developers and contract manufacturers - Learn technical &amp; practical know how from experiences on the ground in Asia - Showcase your cutting edge solutions in front of key China/Asian Biopharma decision makers http://www.biopharmaproduction.com
Biopharma Production and Development China 2015 from Rita Barry
]]> 1072 4 https://cdn.slidesharecdn.com/ss_thumbnails/bdpweek2015-141031015402-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Oncology asia /slideshow/oncology-asia/38728397 oncologyasia-140904234010-phpapp01
With cancer being the fastest growing healthcare priority in the pharmaceutical industry, IBC Asia announces the region's first ever strategic oncology conference focusing on clinical development and market access. Download the brochure &lt;link> now to identify new trends and opportunities in development and commercialization in the region. ONCOLOGY ASIA focuses on the clinical development and effective market access for cancer drugs in Asia. It will cover strategies for developing oncology products and businesses from innovative pipelines, commercializing products, sales and marketing strategies to capture opportunities in Asias markets. Featured sessions from top industry thought leaders: Market Trends and Drivers in the Region James Garner, Head Unit Development Operations, Asia R&D, Sanofi, Singapore What You Need to Know When Marketing Oncology Drugs Dr Paul Cornes, Clinical Oncologist, Bristol Oncology Centre, UK Successful Market Access Strategies for Oncology Drugs Sameer Agarwal, Senior Vice President, Business Center Strategic Marketing, Fresenius Kabi Deutschland GmbH, Germany Clinical Engagement for Successful Oncology Products Dr Anish Desai, Director Medical & Clinical Affairs, Johnson & Johnson, India http://www.oncologyasia.com]]>
With cancer being the fastest growing healthcare priority in the pharmaceutical industry, IBC Asia announces the region's first ever strategic oncology conference focusing on clinical development and market access. Download the brochure &lt;link> now to identify new trends and opportunities in development and commercialization in the region. ONCOLOGY ASIA focuses on the clinical development and effective market access for cancer drugs in Asia. It will cover strategies for developing oncology products and businesses from innovative pipelines, commercializing products, sales and marketing strategies to capture opportunities in Asias markets. Featured sessions from top industry thought leaders: Market Trends and Drivers in the Region James Garner, Head Unit Development Operations, Asia R&D, Sanofi, Singapore What You Need to Know When Marketing Oncology Drugs Dr Paul Cornes, Clinical Oncologist, Bristol Oncology Centre, UK Successful Market Access Strategies for Oncology Drugs Sameer Agarwal, Senior Vice President, Business Center Strategic Marketing, Fresenius Kabi Deutschland GmbH, Germany Clinical Engagement for Successful Oncology Products Dr Anish Desai, Director Medical & Clinical Affairs, Johnson & Johnson, India http://www.oncologyasia.com]]> Thu, 04 Sep 2014 23:40:10 GMT /slideshow/oncology-asia/38728397 rpIBC@slideshare.net(rpIBC) Oncology asia rpIBC With cancer being the fastest growing healthcare priority in the pharmaceutical industry, IBC Asia announces the region's first ever strategic oncology conference focusing on clinical development and market access. Download the brochure &lt;link> now to identify new trends and opportunities in development and commercialization in the region. ONCOLOGY ASIA focuses on the clinical development and effective market access for cancer drugs in Asia. It will cover strategies for developing oncology products and businesses from innovative pipelines, commercializing products, sales and marketing strategies to capture opportunities in Asias markets. Featured sessions from top industry thought leaders: Market Trends and Drivers in the Region James Garner, Head Unit Development Operations, Asia R&D, Sanofi, Singapore What You Need to Know When Marketing Oncology Drugs Dr Paul Cornes, Clinical Oncologist, Bristol Oncology Centre, UK Successful Market Access Strategies for Oncology Drugs Sameer Agarwal, Senior Vice President, Business Center Strategic Marketing, Fresenius Kabi Deutschland GmbH, Germany Clinical Engagement for Successful Oncology Products Dr Anish Desai, Director Medical & Clinical Affairs, Johnson & Johnson, India http://www.oncologyasia.com <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/oncologyasia-140904234010-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> With cancer being the fastest growing healthcare priority in the pharmaceutical industry, IBC Asia announces the region&#39;s first ever strategic oncology conference focusing on clinical development and market access. Download the brochure &amp;lt;link&gt; now to identify new trends and opportunities in development and commercialization in the region. ONCOLOGY ASIA focuses on the clinical development and effective market access for cancer drugs in Asia. It will cover strategies for developing oncology products and businesses from innovative pipelines, commercializing products, sales and marketing strategies to capture opportunities in Asias markets. Featured sessions from top industry thought leaders: Market Trends and Drivers in the Region James Garner, Head Unit Development Operations, Asia R&amp;D, Sanofi, Singapore What You Need to Know When Marketing Oncology Drugs Dr Paul Cornes, Clinical Oncologist, Bristol Oncology Centre, UK Successful Market Access Strategies for Oncology Drugs Sameer Agarwal, Senior Vice President, Business Center Strategic Marketing, Fresenius Kabi Deutschland GmbH, Germany Clinical Engagement for Successful Oncology Products Dr Anish Desai, Director Medical &amp; Clinical Affairs, Johnson &amp; Johnson, India http://www.oncologyasia.com
Oncology asia from Rita Barry
]]> 599 4 https://cdn.slidesharecdn.com/ss_thumbnails/oncologyasia-140904234010-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Offshore RMB 2014 /slideshow/offshore-rmb-2014/38728362 offshorermb1-140904233812-phpapp01
The offshore RMB market has evolved rapidly since 2010 and there have been periods of significant pricing dislocation between onshore and offshore forex and interest rate markets. Over the medium to long term, as the RMB exchange rate becomes more flexible, more products are traded in the offshore RMB market with growing liquidity, and capital account is gradually liberalized, the convergence trend in the pricing of onshore and offshore RMB asset markets is inevitable. &lt;China Money Network, 28 July 2014) The Value of RMB Currency in the Market, Liquidity & Risk will be discussed at IBCs Offshore RMB Seminar (Parkroyal on Beach Road, Singapore * 27 November 2014) by these industry leaders: Joe Ng, Head of Renminbi Payments Product Management - Asia Pacific, Global Transaction Banking, Deutsche Bank, Hong Kong Update Speaker from Gladys, ICBC, Singapore Motasim Iqbal, Head of Transaction Banking, Standard Chartered Bank, Singapore Noritaka Akamatsu, Deputy Head, Office of Regional Economic Integration, Chair, Financial Sector Community of Practice, Asian Development Bank, Philippines Other Key Topics Addressed Include: RMB Policy Liberalization Investing in RMB Capital Markets RMB Cross-Border Settlements Developing of Offshore RMB Operations View more at http://www.offshorermbseminar.com]]>
The offshore RMB market has evolved rapidly since 2010 and there have been periods of significant pricing dislocation between onshore and offshore forex and interest rate markets. Over the medium to long term, as the RMB exchange rate becomes more flexible, more products are traded in the offshore RMB market with growing liquidity, and capital account is gradually liberalized, the convergence trend in the pricing of onshore and offshore RMB asset markets is inevitable. &lt;China Money Network, 28 July 2014) The Value of RMB Currency in the Market, Liquidity & Risk will be discussed at IBCs Offshore RMB Seminar (Parkroyal on Beach Road, Singapore * 27 November 2014) by these industry leaders: Joe Ng, Head of Renminbi Payments Product Management - Asia Pacific, Global Transaction Banking, Deutsche Bank, Hong Kong Update Speaker from Gladys, ICBC, Singapore Motasim Iqbal, Head of Transaction Banking, Standard Chartered Bank, Singapore Noritaka Akamatsu, Deputy Head, Office of Regional Economic Integration, Chair, Financial Sector Community of Practice, Asian Development Bank, Philippines Other Key Topics Addressed Include: RMB Policy Liberalization Investing in RMB Capital Markets RMB Cross-Border Settlements Developing of Offshore RMB Operations View more at http://www.offshorermbseminar.com]]> Thu, 04 Sep 2014 23:38:12 GMT /slideshow/offshore-rmb-2014/38728362 rpIBC@slideshare.net(rpIBC) Offshore RMB 2014 rpIBC The offshore RMB market has evolved rapidly since 2010 and there have been periods of significant pricing dislocation between onshore and offshore forex and interest rate markets. Over the medium to long term, as the RMB exchange rate becomes more flexible, more products are traded in the offshore RMB market with growing liquidity, and capital account is gradually liberalized, the convergence trend in the pricing of onshore and offshore RMB asset markets is inevitable. &lt;China Money Network, 28 July 2014) The Value of RMB Currency in the Market, Liquidity & Risk will be discussed at IBCs Offshore RMB Seminar (Parkroyal on Beach Road, Singapore * 27 November 2014) by these industry leaders: Joe Ng, Head of Renminbi Payments Product Management - Asia Pacific, Global Transaction Banking, Deutsche Bank, Hong Kong Update Speaker from Gladys, ICBC, Singapore Motasim Iqbal, Head of Transaction Banking, Standard Chartered Bank, Singapore Noritaka Akamatsu, Deputy Head, Office of Regional Economic Integration, Chair, Financial Sector Community of Practice, Asian Development Bank, Philippines Other Key Topics Addressed Include: RMB Policy Liberalization Investing in RMB Capital Markets RMB Cross-Border Settlements Developing of Offshore RMB Operations View more at http://www.offshorermbseminar.com <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/offshorermb1-140904233812-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> The offshore RMB market has evolved rapidly since 2010 and there have been periods of significant pricing dislocation between onshore and offshore forex and interest rate markets. Over the medium to long term, as the RMB exchange rate becomes more flexible, more products are traded in the offshore RMB market with growing liquidity, and capital account is gradually liberalized, the convergence trend in the pricing of onshore and offshore RMB asset markets is inevitable. &amp;lt;China Money Network, 28 July 2014) The Value of RMB Currency in the Market, Liquidity &amp; Risk will be discussed at IBCs Offshore RMB Seminar (Parkroyal on Beach Road, Singapore * 27 November 2014) by these industry leaders: Joe Ng, Head of Renminbi Payments Product Management - Asia Pacific, Global Transaction Banking, Deutsche Bank, Hong Kong Update Speaker from Gladys, ICBC, Singapore Motasim Iqbal, Head of Transaction Banking, Standard Chartered Bank, Singapore Noritaka Akamatsu, Deputy Head, Office of Regional Economic Integration, Chair, Financial Sector Community of Practice, Asian Development Bank, Philippines Other Key Topics Addressed Include: RMB Policy Liberalization Investing in RMB Capital Markets RMB Cross-Border Settlements Developing of Offshore RMB Operations View more at http://www.offshorermbseminar.com
Offshore RMB 2014 from Rita Barry
]]> 826 3 https://cdn.slidesharecdn.com/ss_thumbnails/offshorermb1-140904233812-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Generics Asia 2014 /slideshow/generics-asia-2014/37519032 9thgenericsasiacs-140730202420-phpapp02
A successful generic product starts with understanding consumer needs and brand value. On November 4-7 in Singapore, IBC will host the 9th Annual Generics Asia 2014, Asias longest running Generics conference, to help you and your organization understand how to incorporate marketing and partnership into your business strategy. The key topics to be covered at the event include: Regulatory Update and Accelerating Access to New market o A panel of experts from Philippines Chamber of Pharmaceutical Industry, Actavis, Hovid and Pfizer Building Brand Awareness and Delivering New Products with a Cost Effective Strategy o Allan Marx Ancheta, Director Business Development and Strategy, Commercial Innovation and Alliance, Merck Managing Sale Force Effectiveness and Innovative Channels for Generics Products o Marvin Biliwang, Commercial Effectiveness Director, Takeda Pharmaceuticals Establishing Partnerships to Add Value and Build Market Share o Philip Cox, President Director, PT Takeda Indonesia Innovative Models and Super Generics for Prolonging Product Life Cycles o Dr. Shirish Kulkarni, Senior Vice President, Formulation Development, Sun Pharmaceutical ]]>
A successful generic product starts with understanding consumer needs and brand value. On November 4-7 in Singapore, IBC will host the 9th Annual Generics Asia 2014, Asias longest running Generics conference, to help you and your organization understand how to incorporate marketing and partnership into your business strategy. The key topics to be covered at the event include: Regulatory Update and Accelerating Access to New market o A panel of experts from Philippines Chamber of Pharmaceutical Industry, Actavis, Hovid and Pfizer Building Brand Awareness and Delivering New Products with a Cost Effective Strategy o Allan Marx Ancheta, Director Business Development and Strategy, Commercial Innovation and Alliance, Merck Managing Sale Force Effectiveness and Innovative Channels for Generics Products o Marvin Biliwang, Commercial Effectiveness Director, Takeda Pharmaceuticals Establishing Partnerships to Add Value and Build Market Share o Philip Cox, President Director, PT Takeda Indonesia Innovative Models and Super Generics for Prolonging Product Life Cycles o Dr. Shirish Kulkarni, Senior Vice President, Formulation Development, Sun Pharmaceutical ]]> Wed, 30 Jul 2014 20:24:20 GMT /slideshow/generics-asia-2014/37519032 rpIBC@slideshare.net(rpIBC) Generics Asia 2014 rpIBC A successful generic product starts with understanding consumer needs and brand value. On November 4-7 in Singapore, IBC will host the 9th Annual Generics Asia 2014, Asias longest running Generics conference, to help you and your organization understand how to incorporate marketing and partnership into your business strategy. The key topics to be covered at the event include: Regulatory Update and Accelerating Access to New market o A panel of experts from Philippines Chamber of Pharmaceutical Industry, Actavis, Hovid and Pfizer Building Brand Awareness and Delivering New Products with a Cost Effective Strategy o Allan Marx Ancheta, Director Business Development and Strategy, Commercial Innovation and Alliance, Merck Managing Sale Force Effectiveness and Innovative Channels for Generics Products o Marvin Biliwang, Commercial Effectiveness Director, Takeda Pharmaceuticals Establishing Partnerships to Add Value and Build Market Share o Philip Cox, President Director, PT Takeda Indonesia Innovative Models and Super Generics for Prolonging Product Life Cycles o Dr. Shirish Kulkarni, Senior Vice President, Formulation Development, Sun Pharmaceutical <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/9thgenericsasiacs-140730202420-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> A successful generic product starts with understanding consumer needs and brand value. On November 4-7 in Singapore, IBC will host the 9th Annual Generics Asia 2014, Asias longest running Generics conference, to help you and your organization understand how to incorporate marketing and partnership into your business strategy. The key topics to be covered at the event include: Regulatory Update and Accelerating Access to New market o A panel of experts from Philippines Chamber of Pharmaceutical Industry, Actavis, Hovid and Pfizer Building Brand Awareness and Delivering New Products with a Cost Effective Strategy o Allan Marx Ancheta, Director Business Development and Strategy, Commercial Innovation and Alliance, Merck Managing Sale Force Effectiveness and Innovative Channels for Generics Products o Marvin Biliwang, Commercial Effectiveness Director, Takeda Pharmaceuticals Establishing Partnerships to Add Value and Build Market Share o Philip Cox, President Director, PT Takeda Indonesia Innovative Models and Super Generics for Prolonging Product Life Cycles o Dr. Shirish Kulkarni, Senior Vice President, Formulation Development, Sun Pharmaceutical
Generics Asia 2014 from Rita Barry
]]> 654 3 https://cdn.slidesharecdn.com/ss_thumbnails/9thgenericsasiacs-140730202420-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 8th genericsasia2013 /slideshow/8th-genericsasia2013/36733903 8thgenericsasia2013-140708012250-phpapp01
]]>
]]> Tue, 08 Jul 2014 01:22:49 GMT /slideshow/8th-genericsasia2013/36733903 rpIBC@slideshare.net(rpIBC) 8th genericsasia2013 rpIBC <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/8thgenericsasia2013-140708012250-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
8th genericsasia2013 from Rita Barry
]]> 1015 4 https://cdn.slidesharecdn.com/ss_thumbnails/8thgenericsasia2013-140708012250-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Indonesia Healthcare 2014 /slideshow/indonesia-healthcare-2014/35782681 indohealthcare-140612032233-phpapp01
IBCs Indonesia Healthcare conference brings together healthcare leaders to discuss evolving policies, opportunities for private healthcare investment, partnerships, projects and initiatives. Key Conference Themes: Updates on Regulation and the Road Towards Universal Healthcare Coverage Hospital Management & Cutting Edge Healthcare Delivery Standards Digital Marketing and Telehealth Solutions Healthcare Infrastructure Projects, Investments & Development Generics & Access to Medicine Public-Private Partnerships & Collaboration Why You Must Attend This Years Event Understand the proactive steps to take by hospitals, pharmaceutical and insurance companies for the new Universal Healthcare Coverage policy Discover partnerships and investment opportunities in Indonesia Hear different case studies from major hospitals, insurance and pharmaceutical companies Meet and exchange business cards with your peers during the networking sessions Learn how to deliver safe and quality healthcare from other Asian countries]]>
IBCs Indonesia Healthcare conference brings together healthcare leaders to discuss evolving policies, opportunities for private healthcare investment, partnerships, projects and initiatives. Key Conference Themes: Updates on Regulation and the Road Towards Universal Healthcare Coverage Hospital Management & Cutting Edge Healthcare Delivery Standards Digital Marketing and Telehealth Solutions Healthcare Infrastructure Projects, Investments & Development Generics & Access to Medicine Public-Private Partnerships & Collaboration Why You Must Attend This Years Event Understand the proactive steps to take by hospitals, pharmaceutical and insurance companies for the new Universal Healthcare Coverage policy Discover partnerships and investment opportunities in Indonesia Hear different case studies from major hospitals, insurance and pharmaceutical companies Meet and exchange business cards with your peers during the networking sessions Learn how to deliver safe and quality healthcare from other Asian countries]]> Thu, 12 Jun 2014 03:22:32 GMT /slideshow/indonesia-healthcare-2014/35782681 rpIBC@slideshare.net(rpIBC) Indonesia Healthcare 2014 rpIBC IBCs Indonesia Healthcare conference brings together healthcare leaders to discuss evolving policies, opportunities for private healthcare investment, partnerships, projects and initiatives. Key Conference Themes: Updates on Regulation and the Road Towards Universal Healthcare Coverage Hospital Management & Cutting Edge Healthcare Delivery Standards Digital Marketing and Telehealth Solutions Healthcare Infrastructure Projects, Investments & Development Generics & Access to Medicine Public-Private Partnerships & Collaboration Why You Must Attend This Years Event Understand the proactive steps to take by hospitals, pharmaceutical and insurance companies for the new Universal Healthcare Coverage policy Discover partnerships and investment opportunities in Indonesia Hear different case studies from major hospitals, insurance and pharmaceutical companies Meet and exchange business cards with your peers during the networking sessions Learn how to deliver safe and quality healthcare from other Asian countries <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/indohealthcare-140612032233-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> IBCs Indonesia Healthcare conference brings together healthcare leaders to discuss evolving policies, opportunities for private healthcare investment, partnerships, projects and initiatives. Key Conference Themes: Updates on Regulation and the Road Towards Universal Healthcare Coverage Hospital Management &amp; Cutting Edge Healthcare Delivery Standards Digital Marketing and Telehealth Solutions Healthcare Infrastructure Projects, Investments &amp; Development Generics &amp; Access to Medicine Public-Private Partnerships &amp; Collaboration Why You Must Attend This Years Event Understand the proactive steps to take by hospitals, pharmaceutical and insurance companies for the new Universal Healthcare Coverage policy Discover partnerships and investment opportunities in Indonesia Hear different case studies from major hospitals, insurance and pharmaceutical companies Meet and exchange business cards with your peers during the networking sessions Learn how to deliver safe and quality healthcare from other Asian countries
Indonesia Healthcare 2014 from Rita Barry
]]> 3673 7 https://cdn.slidesharecdn.com/ss_thumbnails/indohealthcare-140612032233-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-rpIBC-48x48.jpg?cb=1529635795 Senior Digital Marketing Management Professional B2B Marketing Strategies| Ecommerce Specialist | Integrated Marketing Strategy Accomplished, innovative Digital Marketing Manager with almost a decade of continually progressive experience in delivering comprehensive B2B and digital marketing leadership, acquiring the ability to design and execute targeted digital marketing initiatives, integrated marketing programs, and digital marketing channels. Known as a game changer, with a reputation for utilizing the newest technologies and platforms to drive digital marketing strategy. Solid and sharp team leader with an uninterrupted record of success and the distinct abil... http://www.ibc-asia.com https://cdn.slidesharecdn.com/ss_thumbnails/powersourcemagazinemay20162copy-160512152739-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/the-time-for-siem/61953590 The time for SIEM https://cdn.slidesharecdn.com/ss_thumbnails/rkon-consequences-of-combining-160311153530-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/factors-to-keep-in-mind-when-youre-considering-cloud-storage-services/59428142 Factors to keep in min... https://cdn.slidesharecdn.com/ss_thumbnails/rkon-why-seim-fails-160308163924-thumbnail.jpg?width=320&height=320&fit=bounds rpIBC/why-so-many-siem-implmentations-fail Why so many SIEM Implm...